Sino Biopharmaceutical Limited (SBMFF)
- Previous Close
0.3149 - Open
0.3149 - Bid --
- Ask --
- Day's Range
0.3149 - 0.3149 - 52 Week Range
0.3149 - 0.5440 - Volume
500 - Avg. Volume
874 - Market Cap (intraday)
6.428B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
31.49 - EPS (TTM)
0.0100 - Earnings Date --
- Forward Dividend & Yield 0.01 (2.03%)
- Ex-Dividend Date Jun 11, 2024
- 1y Target Est
--
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection. It also provides surgery/analgesia medicines comprising Debaian cataplasms and Gaisanchun soft capsules; and cardio-cerebral vascular medicines, including Yilunping and Kaina tablets. In addition, the company is involved in the long term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
www.sinobiopharm.comRecent News: SBMFF
Performance Overview: SBMFF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SBMFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBMFF
Valuation Measures
Market Cap
6.43B
Enterprise Value
6.43B
Trailing P/E
22.35
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
1.41
Enterprise Value/Revenue
0.25
Enterprise Value/EBITDA
1.09
Financial Highlights
Profitability and Income Statement
Profit Margin
8.90%
Return on Assets (ttm)
5.33%
Return on Equity (ttm)
12.12%
Revenue (ttm)
26.2B
Net Income Avi to Common (ttm)
1.85B
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
12.56B
Total Debt/Equity (mrq)
32.96%
Levered Free Cash Flow (ttm)
--
Company Insights: SBMFF
SBMFF does not have Company Insights